CONTACT
+91 80 2808 2808
info@biocon.com

Press Releases 2017

Biocon  /  News – Posts  /  Press Releases  /  Press Releases 2017

Biocon and Mylan’s Biosimilar Trastuzumab Receives Approval from ANVISA, Brazil Through Their Partner Libbs
  • Fri, 29-Dec-2017
  • Posted by: BIOCON
No Comments

U.S. FDA Approves Mylan and Biocon´s OgivriTM the First Biosimilar for Trastuzumab, for the Treatment of HER2­Positive Breast and Gastric Cancers
  • Fri, 01-Dec-2017
  • Posted by: BIOCON
No Comments

European Medicines Agency Accepts Marketing Authorization Applications for Mylan and Biocon´s Proposed Biosimilars Trastuzumab and Pegfilgrastim
  • Fri, 01-Dec-2017
  • Posted by: BIOCON
No Comments

Biocon Launches KRABEVA® − Biosimilar Bevacizumab for Treating Several Types of Cancer in India
  • Thu, 23-Nov-2017
  • Posted by: BIOCON
No Comments

Biocon Q2FY18 Revenues at Rs 1019 Crore; EBITDA at Rs 233 Crore; Net Profit at Rs 69 Crore
  • Thu, 26-Oct-2017
  • Posted by: BIOCON
No Comments

Biocon Ranked Among Top 10 Global Pharma & Biotech Employers
  • Wed, 25-Oct-2017
  • Posted by: BIOCON
No Comments

JDRF Supports Biocon Study of Novel, Fast-acting Oral Insulin Tregopil for Type 1 Diabetes Treatment
  • Wed, 06-Sep-2017
  • Posted by: BIOCON
No Comments

Biocon Reports Q1FY18 Revenue at Rs 988 Crore; EBITDA at Rs 246 Crore; Net Profit at Rs 81 Crore
  • Thu, 27-Jul-2017
  • Posted by: BIOCON
No Comments

FDA Oncologic Drugs Advisory Committee Unanimously Recommends Approval of Mylan and Biocon’s Proposed Biosimilar Trastuzumab
  • Fri, 14-Jul-2017
  • Posted by: BIOCON
No Comments

Mylan and Biocon Present Clinical Data on Insulin Glargine at the American Diabetes Association’s 77th Scientific Sessions
  • Sun, 11-Jun-2017
  • Posted by: BIOCON
No Comments
  • 1
  • 2
Report adverse event/ side effects and/or product complaints for Biocon products.

* Safe Harbour | Privacy Policy | Terms of Use © 2023, Biocon. All Rights Reserved
Share